Immunogenic sugar moieties of prostate cancers
Immunogenic sugar moieties of prostate cancers
批准号:
8125080
负责人:
DENONG WANG
金额:
$42.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-06 至 2015-06-30
关键词:
AntibodiesAntigensAutoantibodiesAutoantigensBenign Prostatic HypertrophyBiological AssayBiological MarkersBiopsyCancer PatientCarbohydrate SequenceCarbohydratesCellsCharacteristicsClinicalClinical ResearchCollectionCoupledDetectionDevelopmentDiagnosisDiagnosticDifferential DiagnosisEnzyme-Linked Immunosorbent AssayEpitopesFlow CytometryGleason Grade for Prostate CancerGlobo-HGlycoproteinsGoalsHumanImmunoassayIndividualInternationalInvestigationLigandsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMannoseMasksMass Spectrum AnalysisMeasuresMonitorOligosaccharidesOutcomePatientsPolysaccharidesProstateProstate-Specific AntigenProteinsReagentRecordsResearchResearch PersonnelScreening procedureSerumSerum MarkersSpecimenTechnologyTherapeutic InterventionThompson-Friedenreich AntigenTissue BankingTissue BanksTissuesTumor-Associated Carbohydrate Antigensbaseimmunogenicmanmennoveloutcome forecastprognosticprogramsserological markersugartumor progressionuser-friendly
中文摘要
描述(由申请人提供):该项目汇集了在高通量平台上建立研究记录的研究人员,这些平台包括碳水化合物微阵列、新糖脂(NGL)技术和用于发现碳水化合物配体的质谱仪、用于高灵敏度检测细胞和血清标志物的流式细胞仪(Hi-D FACS),以及第一个用于检测前列腺特异性抗原(PSA)的国际标准。该团队的主要任务是识别和表征免疫生物标记物,并为临床和研究应用开发高灵敏度的分析方法。该项目的最终目标是确定新的血清生物标志物,用于前列腺癌的检测和癌症进展的监测。在初步调查中,他们已经在前列腺癌中确定了一些基于碳水化合物的生物标记物。此外,他们还使用碳水化合物微阵列检测到了其中一些的自身抗体。他们假设,这些异常表达的碳水化合物是免疫原性的,能够在前列腺癌受试者中诱导特定的自身抗体。检测血清中的这种抗体可以检测前列腺癌及其侵袭性进展。在这个项目中,合作小组计划通过表征保存在前列腺癌组织库中的大量分类良好的血清和组织样本来检验他们的假设。他们计划1)确定针对甘露糖簇和其他不正常表达的A/-糖链的抗碳水化合物自身抗体是否可以区分患有BPH和前列腺癌的男性和/或预测侵袭性和进展性前列腺癌;2)确定前列腺癌受试者中是否存在针对其他碳水化合物自身抗原的血清抗体,并评估其诊断和预后价值;3)确定个体血清中某些抗碳水化合物抗体的存在是否与前列腺癌中相应糖表位的异常表达相关;4)确定单抗AE3和G1识别的HCA和其他癌症相关糖蛋白的糖表位的碳水化合物O-糖链序列;以及5)使用新的血清学标记建立高灵敏度和用户友好的免疫分析方法,以促进前列腺癌的大规模临床研究。
英文摘要
DESCRIPTION (provided by applicant): This project brings together researchers who have established research track records in high-throughput platforms of carbohydrate microarrays, neoglycolipid (NGL) technology coupled with mass spectrometry for carbohydrate ligand discovery, flow cytometry (Hi-D FACS) for highly-sensitive detection of cell and serum markers, and the first international standard for detection of prostate-specific antigen (PSA). The thrust of this team is identification and characterization of immunological biomarkers and development of highly sensitive assays for clinical and research applications. The ultimate goal of this project is to identify novel serum biomarkers for detection of prostate cancer and monitoring of cancer progression. In preliminary investigations, they have identified a number of carbohydrate-based biomarkers in prostate cancers. In addition, they have detected autoantibodies to some of these using carbohydrate microarrays. They hypothesize that these aberrantly expressed carbohydrates are immunogenic and are able to induce specific autoantibodies in prostate cancer subjects. Detection of such antibodies in serum could allow detection of prostate cancer and its aggressive progression. In this project, collaborating group plan to examine their hypotheses by characterizing a large-collection of well-categorized serum and tissue specimens preserved in their prostate cancer tissue banks. They plan to 1) determine whether anti-carbohydrate autoantibodies specific for Mannose-clusters and other A/-glycans not normally expressed can distinguish between men with BPH and prostate cancer and/or predict the aggressive and progressive prostate cancers; 2) determine whether serum antibodies specific for other carbohydrate autoantigens are present in prostate cancer subjects and evaluate their diagnostic and prognostic values; 3) determine whether the presence of certain anti-carbohydrate antibodies in the serum of an individual correlates with the aberrant expression of corresponding glyco-epitopes in the prostate cancer; 4) determine the carbohydrate O-glycan sequences of glyco-epitopes of HCA and other cancer-associated glycoproteins that are recognized by mAb AE3 and G1; and 5) establish highly sensitive and user-friendly immunoassays using novel serological markers to facilitate a large-scale clinical study of prostate cancer.
期刊论文(34)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The neoglycolipid (NGL)-based oligosaccharide microarray system poised to decipher the meta-glycome.
DOI:
10.1016/j.cbpa.2014.01.007
发表时间:
2014-02
期刊:
CURRENT OPINION IN CHEMICAL BIOLOGY
影响因子:
7.8
作者:
[Palma, Angelina S., Feizi, Ten, Childs, Robert A., Chai, Wengang, Liu, Yan]
通讯作者:
Liu, Yan
N-glycan Cryptic Antigens as Active Immunological Targets in Prostate Cancer Patients.
N-聚糖隐性抗原作为前列腺癌患者的主动免疫靶点。
DOI:
10.4172/jpb.1000218
发表时间:
2012
期刊:
Journal of proteomics & bioinformatics
影响因子:
--
作者:
[Wang,Denong]
通讯作者:
Wang,Denong
DOI:
10.1007/978-3-319-55947-6_15
发表时间:
2017
期刊:
Advances in experimental medicine and biology
影响因子:
--
作者:
[Wang D, Wu L, Liu X]
通讯作者:
Liu X
DOI:
10.1021/pr900452s
发表时间:
2009-11
期刊:
JOURNAL OF PROTEOME RESEARCH
影响因子:
4.4
作者:
[Zhou, Xichun, Turchi, Craig, Wang, Denong]
通讯作者:
Wang, Denong
Multifaceted approaches including neoglycolipid oligosaccharide microarrays to ligand discovery for malectin.
多方面的方法,包括新糖脂寡糖微阵列来发现 malectin 的配体。
DOI:
10.1016/s0076-6879(10)78013-7
发表时间:
2010
期刊:
Methods in enzymology
影响因子:
--
作者:
[Palma,AngelinaS, Liu,Yan, Muhle-Goll,Claudia, Butters,TerryD, Zhang,Yibing, Childs,Robert, Chai,Wengang, Feizi,Ten]
通讯作者:
Feizi,Ten
共 26 条
Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomas
-
批准号:10436334
-
项目类别:
-
资助金额:$30.47万
-
财政年份:2021
-
负责人:DENONG WANG
-
依托单位:
Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomas
-
批准号:10267450
-
项目类别:
-
资助金额:$27.12万
-
财政年份:2021
-
负责人:DENONG WANG
-
依托单位:
IMMUNOGENIC SUGAR MOIETIES OF HCMV
-
批准号:9245147
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2017
-
负责人:DENONG WANG
-
依托单位:
B-1 B cell responses to oligomannosyl antigens of HIV-1
-
批准号:9078722
-
项目类别:
-
资助金额:$88.36万
-
财政年份:2015
-
负责人:DENONG WANG
-
依托单位:
A T-independent pathway of B cell responses to oligomannosyl antigens of HIV-1
-
批准号:8703221
-
项目类别:
-
资助金额:$75.09万
-
财政年份:2013
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7638573
-
项目类别:
-
资助金额:$40.3万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7877784
-
项目类别:
-
资助金额:$45.24万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7479360
-
项目类别:
-
资助金额:$40.39万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7692616
-
项目类别:
-
资助金额:$15.8万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7281012
-
项目类别:
-
资助金额:$42.24万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
T-INDEPENDENT IGA INDUCTION AND HIV-1 VACCINATION
-
批准号:6170336
-
项目类别:
-
资助金额:$24.83万
-
财政年份:1999
-
负责人:DENONG WANG
-
依托单位:
T-INDEPENDENT IGA INDUCTION AND HIV-1 VACCINATION
-
批准号:2873465
-
项目类别:
-
资助金额:$24.54万
-
财政年份:1999
-
负责人:DENONG WANG
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: